Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (TNDM) Financial Performance & Income Statement Overview
Analyze Tandem Diabetes Care, Inc. (TNDM) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Tandem Diabetes Care, Inc. (TNDM) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Tandem Diabetes Care, Inc. TNDM financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $234.42M | $282.65M | $363.29M | $221.91M |
| Cost of Revenue | $116.02M | $125.19M | $238.64M | $109.12M |
| Gross Profit | $118.41M | $157.46M | $124.65M | $112.79M |
| Gross Profit Ratio | $0.51 | $0.56 | $0.34 | $0.51 |
| R&D Expenses | $125.43M | $52.20M | $51.11M | $49.33M |
| SG&A Expenses | $113.85M | $105.84M | $99.64M | $94.24M |
| Operating Expenses | $239.28M | $158.04M | $150.75M | $143.57M |
| Total Costs & Expenses | $355.30M | $283.23M | $389.38M | $252.68M |
| Interest Income | $0.00 | $4.51M | $5.34M | $2.82M |
| Interest Expense | $0.00 | $1.86M | $1.86M | $1.79M |
| Depreciation & Amortization | $4.31M | $4.25M | $4.21M | $4.11M |
| EBITDA | -$116.42M | $6.12M | -$16.54M | -$23.84M |
| EBITDA Ratio | -$0.50 | $0.02 | -$0.05 | -$0.11 |
| Operating Income | -$120.88M | -$582000.00 | -$26.09M | -$30.77M |
| Operating Income Ratio | -$0.52 | -$0.002 | -$0.07 | -$0.14 |
| Other Income/Expenses (Net) | -$1.21M | $598000.00 | $3.48M | $1.03M |
| Income Before Tax | -$122.09M | $16000.00 | -$22.61M | -$29.74M |
| Income Before Tax Ratio | -$0.52 | $0.00 | -$0.06 | -$0.13 |
| Income Tax Expense | $8.47M | -$739000.00 | $637000.00 | $1.07M |
| Net Income | -$130.56M | $755000.00 | -$23.25M | -$30.81M |
| Net Income Ratio | -$0.56 | $0.003 | -$0.06 | -$0.14 |
| EPS | -$1.97 | $0.01 | -$0.35 | -$0.47 |
| Diluted EPS | -$1.97 | $0.01 | -$0.35 | -$0.47 |
| Weighted Avg Shares Outstanding | $66.40M | $65.94M | $65.54M | $64.99M |
| Weighted Avg Shares Outstanding (Diluted) | $66.40M | $66.16M | $65.54M | $64.99M |
Financial performance has remained strong, with revenue growing from $221.91M in Q2 2024 to $234.42M in Q1 2025. Gross profit continued to perform well, with margins at 51% in the latest quarter. Operating income reached -$120.88M in Q1 2025, holding a steady -52% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$116.42M. Net income dropped to -$130.56M, keeping EPS at -$1.97. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan